$0.00
0.00% day before yesterday
Nasdaq, Aug 07, 03:30 pm CET
ISIN
US8091711015
Symbol
SCPS

Scopus Biopharma Inc Stock price

$0.00
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
+0.00 200.00% 1Y
-0.43 99.93% 3Y
-5.92 99.99% 5Y
-5.92 99.99% 10Y
-5.92 99.99% 20Y
Nasdaq, Closing price Fri, Aug 08 2025
+0.00 0.00%
ISIN
US8091711015
Symbol
SCPS
Industry

Key metrics

Basic
Market capitalization
$10.0k
Enterprise Value
$-350.0k
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.0
Financial Health
Equity Ratio
-1,673.3%
Return on Equity
176.9%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
0.3%
Employees
13
Rev per Employee
$0.0
Show more

Is Scopus Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Scopus Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Scopus Biopharma Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Scopus Biopharma Inc forecast:

Buy
86%
Hold
14%

Financial data from Scopus Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '23
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.08 4.08
75% 75%
-
- Research and Development Expense 5.27 5.27
328% 328%
-
-9.34 -9.34
46% 46%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.34 -9.34
46% 46%
-
Net Profit -8.70 -8.70
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Scopus Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. Its drug candidates comprises of combination of cannabidiol-mediated, opioid-sparing anesthetics, synthesis of cannabinoids, and cannabinoid receptor mediating compounds for the treatment of systemic sclerosis. The company was founded on April 18, 2017 and is headquartered in New York, NY.

Head office United States
CEO Morris Laster
Employees 13
Founded 2017
Website scopusbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today